- The use of radiotherapy in the treatment of patients with Merkel cell carcinoma appeared to be well tolerated in a group of site-specific patients with adverse features, according to the results of a study conducted at MSKCC.
- In a paper published in Nature, MSKCC researchers show that the zinc finger protein Ars2 is necessary and sufficient to promote NSC [neural stem cell] self-renewal, and does so by positively regulating the expression of Sox2.
- Lead Investigator Nancy Lee, MD of MSKCC and her team reported that over 90% of patients treated with a combination of the widely used anti-cancer drug bevacizumab with standard chemo-radiation therapy survived for 2 years with no distant metastases and that the disease did not progress in 75% of patients.